Calpainopathy / LGMD R1:
from mechanism to intervention
Limb-girdle muscular dystrophy type R1 (LGMD R1 / calpainopathy) is caused by mutations in the CAPN3 gene. It is progressive, currently without disease-modifying treatment, and affects tens of thousands worldwide. This research programme develops a four-pillar strategy from metabolic stabilisation to precision base editing.
Active · Strategy phase · Clinical horizon 2034–2037LGMD R1 — what we know and what we don't
Calpainopathy is the most common form of limb-girdle muscular dystrophy. It is caused by loss-of-function mutations in CAPN3, which encodes calpain-3 — a muscle-specific calcium-dependent protease essential for sarcomere remodelling and muscle homeostasis.
Without functional calpain-3, muscles undergo progressive fibrosis and atrophy. The disease typically presents in the second or third decade of life and leads to significant disability. There is currently no approved disease-modifying therapy.
The primary research target: The c.2242C>T mutation — one of the most common CAPN3 pathogenic variants — is a point mutation that is in principle correctable by adenine base editing (ABE). The research programme works toward a clinically viable ABE correction strategy for this mutation.
Four-pillar framework
Cell banking and correction
A central component of the research strategy is the establishment of an iPSC bank from LGMD R1 patients carrying the c.2242C>T mutation. This serves two purposes:
Disease modelling
Patient-derived iPSC lines differentiated into skeletal muscle cells provide the primary in vitro model for testing base editing efficiency, specificity, and functional correction. Corrected lines serve as isogenic controls — the gold standard for demonstrating that the editing, not incidental genetic background, is responsible for functional improvement.
Therapeutic banking
Corrected iPSC lines (UCB-ABE, iPSC-ABE) serve as a potential therapeutic resource — autologous cell therapy using gene-corrected cells derived from the patient's own tissue. This strategy avoids immune rejection and is compatible with the clinical horizon of the programme (2034–2037).
AI-augmented research approach
Continuous AI-augmented synthesis of the calpainopathy and base editing literature. The field moves fast — new ABE systems, new AAV serotypes, new anti-fibrotic candidates. AI enables continuous integration of new findings into the research strategy rather than periodic manual literature reviews.
Computational guide RNA design and off-target prediction for ABE correction of c.2242C>T. Tools: BE-Designer, CRISPick, CasOFFinder. Prioritisation of guides by editing window position, PAM availability, and predicted off-target profile. In silico results guide experimental prioritisation.
Protein interaction network analysis of CAPN3 and its interactors — identifying secondary targets for metabolic and anti-fibrotic intervention. AI-augmented pathway analysis (STRING, Reactome) to map downstream consequences of CAPN3 loss and identify druggable nodes.
The EQUORA Institute does not operate a wet laboratory. The computational and strategic research outputs of this programme are designed to be directly usable by academic or clinical collaborators with experimental capacity. The Institute's contribution is the research strategy, the literature synthesis, and the computational groundwork.
Why the timeline is shorter than expected
The field has accelerated on multiple fronts. Four developments directly affect the CAPN3 programme:
Calpainopathy as metabolic myopathy
An emerging research direction treats calpainopathy not as a classical muscular dystrophy — progressive fibrosis and atrophy driven by membrane fragility — but as a metabolic myopathy with a sarcomere remodelling arrest at its core. This has direct therapeutic implications.
PDGFRβ/STAT1 signalling as regenerative brake
A 2026 JCI study identified the PDGFRβ/STAT1/TGF-β signalling axis as a regulatory checkpoint in myocyte fusion and muscle regeneration. In CAPN3-deficient muscle, this axis may be chronically activated — functioning as a "regenerative brake" that prevents satellite cell-mediated repair. PDGFRβ inhibitors (SU16f) or STAT1 inhibitors (fludarabine) are candidate adjunct strategies to enhance regeneration independent of gene correction. This connects to CAPN3's known role in actin-cytoskeleton remodelling and reduced myonuclear accumulation in calpainopathy.
SOCE — store-operated calcium entry dysregulation
University of Florida (Barton / Wei-LaPierre, C3 grant 2022–2025): CAPN3 is essential for proper calcium handling in skeletal muscle. In LGMD2A/R1 mouse models, store-operated calcium entry (SOCE) is abnormally elevated at rest and fails to respond appropriately to exercise. A 2025 C3-funded follow-up grant is now testing SOCE chemical inhibitors in CAPN3-null mouse models and patient-derived muscle cells — making calcium handling modulation an active near-term therapeutic candidate independent of gene correction.
GSK-3β / Wnt-mTOR dysregulation
LGMD2A/R1 patient muscle shows severe reduction in Wnt pathway and mTOR signalling proteins. GSK-3β inhibitors — tideglusib and VP0.7 — restore Wnt and mTOR pathway activity in patient-derived myotubes (Biodonostia / CSIC, 2021). Tideglusib has completed phase 2 trials in Alzheimer's disease, where development was discontinued for lack of efficacy, and remains in clinical development for congenital myotonic dystrophy; it holds no marketing authorisation in the EU or UK for any indication. What makes repurposing evaluation feasible is the existing human safety dataset, rather than any approved status. This is a second metabolic intervention target alongside the NAD+/creatine/mTORC1 axis.
Mitochondrial energy deficit and IκBα/NF-κB dysregulation
Converging evidence from PPARδ agonist and pyruvate experiments in CAPN3-null models validates mitochondrial energy deficit as a therapeutically real node. CAPN3 normally cleaves IκBα, releasing NF-κB for muscle adaptation signalling — in CAPN3 deficiency, NF-κB is suppressed, leading to myonuclear apoptosis and transcriptional adaptation failure. The weekly prednisolone GR–KLF15 mechanism may partially compensate for this lost NF-κB regulation, explaining its anabolic profile at intermittent dosing.
The cardiac toxicity problem — and its resolution
Early AAV-mediated CAPN3 gene transfer experiments in mice produced dose-dependent mortality from cardiac fibrosis — CAPN3 ectopic expression in the heart causes unregulated proteolysis. This was the primary obstacle to clinical translation.
The Genethon team (Isabelle Richard) solved this through two parallel strategies: (1) muscle-specific promoters including the CAPN3 promoter itself, combined with cardiac miRNA-208a target sequences in the 3′ UTR to suppress cardiac expression; (2) identification that the cardiac toxicity is species-specific — caused by titin splice isoform differences between mice and primates. In NHPs (and humans), titin splicing provides a buffering capacity for CAPN3 activity that mice lack. AAV9-desmin-hCAPN3 in NHPs showed no cardiac toxicity and therapeutic skeletal muscle expression.
This means the mouse cardiac toxicity data does not translate to humans — but the delivery construct must still use cardiac-suppressing design elements as a safety requirement. This is why muscle-specific promoters (tMCK, desmin, CAPN3 promoter + miR-208a target) are a non-negotiable design feature of any CAPN3 gene therapy construct.
Monitoring tools and patient data
A 2026 publication identified urinary N-terminal titin fragment as a biomarker in a LGMD2A/R1 cohort. Titin fragments released by abnormal CAPN3-mediated cleavage are detectable in urine — providing a non-invasive disease activity marker. Relevant for: monitoring disease progression, measuring response to metabolic or anti-fibrotic interventions, and tracking SOCE modulator efficacy without repeated muscle biopsy.
Coalition to Cure Calpain 3 (C3) operates a patient-powered natural history registry with 200+ participants from 41 countries in its first year. The registry has already supported recruitment for three clinical research studies. This is a parallel and complementary resource to the JOURNEY natural history study — and a direct route to connecting with the global calpainopathy research community.
Patient-derived material
The programme has access to banked patient-derived biological material suitable for iPSC derivation, held for research use. The nature of the material and the genotype it carries are discussed directly with prospective academic collaborators rather than set out here. Access to patient-matched material is an unusual starting position for a computational programme, and it enables a tiered experimental approach once collaboration is established:
Differentiation to skeletal muscle allows direct testing of KLF15 transcriptional response, mitochondrial biogenesis, IκBα/NF-κB status, and sarcolemmal repair in patient-derived cells. ABE correction of the same line produces an isogenic control — the gold standard for demonstrating that the editing, rather than genetic background, is responsible for functional recovery.
An independently derived second line supports validation of the primary result, and serves as a direct model for the fibrosis and niche pillar. Mesenchymal-to-myofibroblast transition in the CAPN3-deficient context can be studied directly, and anti-fibrotic candidates (pirfenidone, losartan, TGF-β inhibitors) tested on patient-matched material.
What the wider computational genomics field is producing
The CAPN3 programme sits within a rapidly accelerating field. Five platform-level developments are directly relevant — not as CAPN3-specific research, but as enabling technologies that reshape what is possible for any rare muscle disease.
1 — Prime editing enters clinical validation (2025)
Prime Medicine's PM359 produced the first human prime editing data: 82% of colony-forming cells with at least one repaired allele, under 2% unintended edits, in a Phase 1/2 trial for chronic granulomatous disease. Prime editing can make all 12 types of point mutation corrections plus small insertions and deletions — expanding the addressable mutation space beyond ABE's A→G conversions. For CAPN3, this means the c.550delA frameshift — not reachable by ABE — becomes a tractable prime editing target. David Liu won the 2025 Breakthrough Prize for base and prime editing.
2 — N-of-1 bespoke CRISPR: regulatory paradigm shift (2025–2026)
Baby KJ (CHOP/Penn Medicine, February 2025): first personalized in vivo CRISPR base editing therapy, designed and manufactured in 6 months for a unique CPS1 deficiency mutation. LNP-delivered ABE8e, 42% liver cell correction in patient-specific mouse model, no serious adverse effects. The FDA subsequently opened a draft guidance pathway for bespoke genome editing therapies — a regulatory precedent that could accelerate N-of-1 approaches for ultra-rare CAPN3 mutations. Proof that individualized gene editing is now a realistic clinical strategy, not a distant aspiration.
3 — LNP delivery to skeletal muscle: a paradigm shift (2025–2026)
Until 2024, LNPs were considered liver-tropism delivery vehicles — unsuitable for skeletal muscle. This is changing rapidly. A Myomerger-derived peptide (Laporte lab, IGBMC, Nov 2025) enhances skeletal muscle tropism of LNPs while reducing liver transduction. World Muscle Society Congress 2025 featured two keynotes on LNP delivery to muscle — a first. LNPs that target satellite cells (not just mature fibres) offer a fundamental advantage over AAV: sustained editing after muscle regeneration. This directly affects the CAPN3 delivery strategy: LNP-delivered compact ABE targeting muscle may become viable before AAV-based approaches reach the clinic.
4 — Engineered VLPs: non-viral, size-unlimited delivery (2022–2026)
Engineered virus-like particles (eVLPs, David Liu lab / Banskota et al. 2022; extended to prime editing RNPs 2024) deliver base editors and prime editors as ribonucleoproteins — not DNA. Key advantages: (1) no AAV cargo size limit — prime editors and large ABEs fit without split-intein; (2) transient expression reduces off-target exposure; (3) no viral genome integration risk; (4) glycoprotein swapping changes tissue tropism. In vivo base editing at therapeutic levels in liver, retina, and inner ear. Muscle tropism VLPs are the logical next development — directly relevant to CAPN3 ABE delivery without the cardiac-safety constraints of AAV-CAPN3 vectors.
5 — AlphaFold3 + AI for drug target identification (2024–2026)
AlphaFold3 (Nobel Prize in Chemistry 2024, Hassabis/Jumper/Baker) predicts structures of protein complexes — protein-protein, protein-DNA, protein-RNA, protein-ligand — with 76% accuracy in protein-ligand docking, 1.8× improvement over prior methods. Open-sourced November 2024. Directly applicable to the CAPN3 programme: (1) modelling the CAPN3-titin interaction at atomic resolution to understand why cardiac toxicity is species-specific; (2) identifying druggable pockets in the PDGFRβ/STAT1 and GSK-3β pathways for adjunct therapy design; (3) predicting guide RNA / target DNA structure for ABE off-target assessment. The AI-augmented research methodology of the EQUORA Institute is now running on the same tools the best structural biology labs in the world use.
Research roadmap — revised 2026
Strategy and computational phase. Four-pillar framework developed. In silico guide RNA design for c.2242C>T using ABE8eY149V and compact ABE systems. Metabolic and anti-fibrotic candidate identification. Field monitoring: NCH/Sarepta IND progress.
Collaboration initiation + parallel track monitoring. Engagement with academic partners for in vitro ABE validation. iPSC banking strategy finalized. NCH/Sarepta clinical trial expected to initiate — observing and learning from the gene replacement track. First working paper submitted on computational strategy.
In vitro ABE validation. c.2242C>T correction efficiency in patient-derived iPSC lines using compact ABE + ABE8eY149V. Off-target profiling. Anti-fibrotic and metabolic intervention testing in parallel. Gene replacement trial (NCH/Sarepta track) generating first human safety data — informing delivery strategy for ABE track.
In vivo ABE studies. Animal model ABE correction. Delivery strategy: single-vector compact ABE via AAVrh74 or AAV9. IND-enabling studies. Gene replacement trial may have early efficacy data by this point — establishing the clinical benchmark for ABE to exceed.
Clinical horizon for ABE. First-in-human ABE studies for c.2242C>T, contingent on preclinical success. Gene replacement may be approved or in late-stage trials by this point — ABE offers the advantage of permanent, precise correction vs. gene addition.
How this page was produced
Active · Strategy phase · Clinical horizon 2034–2037
Literature discovery and synthesis, candidate identification, computational modelling, and first drafts of this page. Volume and speed are the machine's contribution; none of it is treated as verified on its own.
Claims traced to primary sources rather than to summaries of them. Contested claims run through assert–refute–adjudicate across independent model families. Errors found after publication are corrected on this page with their date.
Problem selection, the evidentiary bar, and the decision to publish rest with Pölö (László Papp), EQUORA Institute, who holds editorial responsibility for this page.
Stated in the Methodology section, per component. Where a source is a preprint, a pilot study, a single trial or a modelled estimate, the page says so at the point of use.
v1.0 · 2026-06-27
Nothing on this page is a treatment recommendation. It describes a research strategy at the computational and planning stage. LGMD R1 / calpainopathy currently has no approved disease-modifying therapy, and none of the four pillars described here is an available treatment.
The compounds named on this page are research candidates, not options to act on. Several are unapproved for any indication, some have had development discontinued for lack of efficacy, and others are approved only for unrelated conditions. Their appearance here reflects a hypothesis worth testing, not evidence of benefit in calpainopathy.
Do not start, stop or change any medication on the basis of this page. This applies with particular force to glucocorticoid regimens, including the weekly-pulsed protocol discussed above: the human data is a small pilot study, and glucocorticoids carry substantial known risks that require clinical supervision. Decisions about treatment belong to a patient's own neuromuscular clinician.
The gene editing approaches described here are preclinical. Base editing and prime editing for CAPN3 are not clinically available for this condition anywhere. The timeline on this page is a research projection, and research projections of this kind frequently slip.
Editing strategies are variant-specific and do not generalise. An approach applicable to one CAPN3 variant is usually not applicable to another. Nothing here supports an inference about any individual's own genotype.
The EQUORA Institute is not a clinical provider. It does not diagnose, does not treat, does not supply materials to patients, and does not enrol anyone in trials. Families looking for a route into research should speak with a neuromuscular specialist centre and consider the disease registries and natural history studies named above, which are the established paths to trial access.
Declaration of interest: the lead investigator has a personal connection to this disease area. It is declared here as a matter of research practice. The scientific rationale on this page stands on the published literature and is stated so that it can be assessed without reference to that connection.
Principal investigator
Pölö (László Papp) — Founder, EQUORA Institute. Academic collaborators, clinical researchers, or patient organisations working in LGMD R1 / calpainopathy: lpapp@equora.institute